• NEWS
• COMPANY
• PRODUCTS
• SERVICES
• RESEARCH
• CONTACT

To date, the diagnosis of  SIRS versus sepsis is based primarily on clinical criteria which lack the required sensitivity and specificity. Novel biomarker are urgently needed to correctly and timely identify an infection as the underlying cause of a systemic host response. According to the FDA, biomarker are biological products (e.g. transcripts, proteins, hormones) that are objectively measured and evaluated as indicators of normal biologic or pathogenic processes or pharmacological responses to a therapeutic intervention. Leveraging the "Jena Sepsis Register", SIRS-Lab has developed a unique competence in mapping the occurrence and the complex molecular framework of sepsis - including the individual transition from SIRS to sepsis.

Gene Activity Biomarker 

As host cells undergo marked reprogramming of their transcriptome already at an early stage during infection, gene expression profiling is a promising way to improve sepsis diagnostics. SIRS-Lab has demonstrated in a multi-centre study that distinct classificator substantially improve sensitivity and specificity but also to shorten the time to diagnosis and adequate therapy. The resulting products will be the first-in-class IVD product analyzing gene activity for the monitoring of the immunoinflammatory response to infection in blood samples.

Protein Biomarker Identification